Identification

Name
Teriflunomide
Accession Number
DB08880  (EXPT00364, DB03805)
Type
Small Molecule
Groups
Approved
Description

Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

Structure
Thumb
Synonyms
  • (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide
  • A 77-1726
  • A 771726
  • A771726
  • HMR 1726
  • Teriflunomida
  • Tériflunomide
  • Teriflunomidum
External IDs
A-771726 / A77 1726 / HMR-1726 / HMR1726
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AubagioTablet14 mgOralSanofi Genzyme, a Division of Sanofi Aventis Canada Inc2013-11-15Not applicableCanada
AubagioTablet, film coated14 mgOralSanofi Aventis Groupe2013-08-26Not applicableEu
AubagioTablet, film coated14 mg/1OralGenzyme Corporation2013-05-012054-12-31Us
AubagioTablet, film coated14 mgOralSanofi Aventis Groupe2013-08-26Not applicableEu
AubagioTablet, film coated14 mgOralSanofi Aventis Groupe2013-08-26Not applicableEu
AubagioTablet, film coated7 mg/1OralGenzyme Corporation2013-05-012054-12-31Us
AubagioTablet, film coated14 mgOralSanofi Aventis Groupe2013-08-26Not applicableEu
AubagioTablet, film coated14 mgOralSanofi Aventis Groupe2013-08-26Not applicableEu
Categories
UNII
1C058IKG3B
CAS number
163451-81-8
Weight
Average: 270.2073
Monoisotopic: 270.061612157
Chemical Formula
C12H9F3N2O2
InChI Key
UTNUDOFZCWSZMS-YFHOEESVSA-N
InChI
InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
IUPAC Name
(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
SMILES
C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F

Pharmacology

Indication

Used in the treatment of relapsing forms of multiple sclerosis (MS).

Structured Indications
Pharmacodynamics

Teriflunomide is an immunomodulatory agent that decreases the amount of activated CNS lymphocytes, which results in anti-inflammatory and antiproliferative effects.

Mechanism of action

The exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.

TargetActionsOrganism
UDihydroorotate dehydrogenase (quinone), mitochondrial
inhibitor
Human
Absorption

After oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours.

Volume of distribution

After a single intravenous dose, the volume of distribution is 11 L.

Protein binding

Teriflunomide is extensively plasma protein bound(>99%).

Metabolism

Teriflunomide mainly undergoes hydrolyis to minor metabolites. Other minor metabolic pathways include oxidation, N-acetylation and sulfate conjugation. Teriflunomide is not metabolized by CYP450 or flavin monoamine oxidase.

Route of elimination

Teriflunomide is eliminated unchanged and mainly through bile. Specifically 37.5% is eliminated in the feces and 22.6% in urine.

Half life

The median half-life is 18 to 19 days.

Clearance

After a single IV dose, teriflunomide has a total body clearance of 30.5 mL/h.

Toxicity

Teriflunomide is contraindicated in pregnant women or women of childbearing age due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe hepatic impairment due to reports of hepatotoxicity, hepatic failure, and death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 5-androstenedione.Experimental, Illicit
AbciximabTeriflunomide may increase the anticoagulant activities of Abciximab.Approved
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Teriflunomide.Approved
AcebutololTeriflunomide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Teriflunomide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Acemetacin.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Teriflunomide.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Teriflunomide.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Teriflunomide.Approved, Vet Approved
AciclovirThe serum concentration of Aciclovir can be increased when it is combined with Teriflunomide.Approved
AclarubicinTeriflunomide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
Activated charcoalThe serum concentration of Teriflunomide can be decreased when it is combined with Activated charcoal.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Teriflunomide.Approved
Adefovir DipivoxilThe serum concentration of Adefovir Dipivoxil can be increased when it is combined with Teriflunomide.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Teriflunomide.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
AlclofenacThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alendronic acid.Approved
AliskirenTeriflunomide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alminoprofen.Experimental
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Teriflunomide.Approved, Investigational
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Teriflunomide.Approved, Withdrawn
AlprenololTeriflunomide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Teriflunomide.Approved, Investigational
AlvocidibThe serum concentration of Alvocidib can be increased when it is combined with Teriflunomide.Experimental, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Teriflunomide.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Amcinonide.Approved
AmikacinTeriflunomide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTeriflunomide may decrease the antihypertensive activities of Amiloride.Approved
Aminohippuric acidThe serum concentration of Aminohippuric acid can be increased when it is combined with Teriflunomide.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Teriflunomide.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Teriflunomide.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Teriflunomide.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Teriflunomide.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Teriflunomide.Approved
AmrubicinTeriflunomide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe serum concentration of Anagrelide can be decreased when it is combined with Teriflunomide.Approved
AncrodTeriflunomide may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Teriflunomide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Anisodamine.Investigational
annamycinTeriflunomide may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.Approved
Antithrombin III humanTeriflunomide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Teriflunomide.Approved
ApocyninThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Apocynin.Investigational
ApramycinTeriflunomide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Teriflunomide.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Teriflunomide.Approved, Investigational
ArbekacinTeriflunomide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTeriflunomide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTeriflunomide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTeriflunomide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Teriflunomide.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Atamestane.Investigational
AtenololTeriflunomide may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.Approved
AV650The serum concentration of AV650 can be decreased when it is combined with Teriflunomide.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Teriflunomide.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.Withdrawn
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Teriflunomide.Approved
BalsalazideTeriflunomide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Teriflunomide.Investigational
BecaplerminTeriflunomide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTeriflunomide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTeriflunomide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Teriflunomide.Approved, Investigational
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Teriflunomide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Teriflunomide.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Benzydamine.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Teriflunomide.Approved
BenzylpenicillinThe serum concentration of Benzylpenicillin can be increased when it is combined with Teriflunomide.Approved, Vet Approved
BeraprostThe metabolism of Beraprost can be decreased when combined with Teriflunomide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Betamethasone.Approved, Vet Approved
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.Approved
BevantololTeriflunomide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Teriflunomide.Approved, Investigational
BisoprololTeriflunomide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTeriflunomide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTeriflunomide may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Teriflunomide.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Teriflunomide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bucillamine.Investigational
BucindololTeriflunomide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bufexamac.Experimental
BufuralolTeriflunomide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bumadizone.Experimental
BumetanideTeriflunomide may decrease the diuretic activities of Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Teriflunomide.Approved, Investigational
BupranololTeriflunomide may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Teriflunomide.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Teriflunomide.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Teriflunomide.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Teriflunomide.Experimental
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Teriflunomide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Teriflunomide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Teriflunomide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Teriflunomide.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Teriflunomide.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Teriflunomide.Approved
CarboplatinThe serum concentration of Carboplatin can be increased when it is combined with Teriflunomide.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Teriflunomide.Approved
CarmustineThe serum concentration of Carmustine can be decreased when it is combined with Teriflunomide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Teriflunomide.Approved, Vet Approved, Withdrawn
CarteololTeriflunomide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Teriflunomide.Experimental
CefacetrileThe serum concentration of Cefacetrile can be increased when it is combined with Teriflunomide.Approved
CefazolinThe serum concentration of Cefazolin can be increased when it is combined with Teriflunomide.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Teriflunomide.Approved, Investigational
CeliprololTeriflunomide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Teriflunomide.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Teriflunomide.Withdrawn
CertoparinTeriflunomide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Teriflunomide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Teriflunomide.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide.Approved
CholesterolThe serum concentration of Cholesterol can be increased when it is combined with Teriflunomide.Experimental, Investigational
CholestyramineThe serum concentration of Teriflunomide can be decreased when it is combined with Cholestyramine.Approved
Cholic AcidThe serum concentration of Cholic Acid can be increased when it is combined with Teriflunomide.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Teriflunomide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ciclesonide.Approved, Investigational
CidofovirThe serum concentration of Cidofovir can be increased when it is combined with Teriflunomide.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Teriflunomide.Approved
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Teriflunomide.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Teriflunomide.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Teriflunomide.Approved, Investigational
CinoxacinTeriflunomide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Teriflunomide.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.Approved
Citric AcidTeriflunomide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
CladribineThe serum concentration of Cladribine can be increased when it is combined with Teriflunomide.Approved, Investigational
ClenbuterolThe serum concentration of Clenbuterol can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofarabineThe serum concentration of Clofarabine can be increased when it is combined with Teriflunomide.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.Approved
ClonixinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Teriflunomide.Vet Approved
CloranololTeriflunomide may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Teriflunomide.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Teriflunomide.Approved
ColesevelamThe serum concentration of Teriflunomide can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Teriflunomide can be decreased when it is combined with Colestipol.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Teriflunomide.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Teriflunomide.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.Approved
CurcuminThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Curcumin.Investigational
Cyclic Adenosine MonophosphateThe serum concentration of Cyclic Adenosine Monophosphate can be increased when it is combined with Teriflunomide.Experimental
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Teriflunomide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Teriflunomide.Approved, Investigational
CyclosporineTeriflunomide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with D-Limonene.Investigational
Dabigatran etexilateTeriflunomide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Teriflunomide.Approved
DacarbazineThe serum concentration of Dacarbazine can be decreased when it is combined with Teriflunomide.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Teriflunomide.Approved
DalteparinTeriflunomide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTeriflunomide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Teriflunomide.Approved, Investigational
DarexabanTeriflunomide may increase the anticoagulant activities of Darexaban.Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Teriflunomide.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Teriflunomide.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deflazacort.Approved
DelafloxacinThe serum concentration of Delafloxacin can be increased when it is combined with Teriflunomide.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Teriflunomide.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide.Approved
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.Approved
DesirudinTeriflunomide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Teriflunomide.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone isonicotinate.Vet Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be decreased when it is combined with Teriflunomide.Approved, Illicit, Investigational, Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Teriflunomide.Approved, Investigational
DextranTeriflunomide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Teriflunomide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Teriflunomide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Teriflunomide may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Teriflunomide.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Teriflunomide.Approved, Illicit, Vet Approved
DibekacinTeriflunomide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Teriflunomide.Approved, Vet Approved
DicoumarolTeriflunomide may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be increased when it is combined with Teriflunomide.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Teriflunomide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Teriflunomide.Approved
DihydrostreptomycinTeriflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Teriflunomide.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Teriflunomide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Teriflunomide.Approved, Vet Approved
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Teriflunomide.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Teriflunomide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Teriflunomide.Approved, Investigational
DrospirenoneTeriflunomide may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Droxicam.Approved
DuloxetineThe serum concentration of Duloxetine can be decreased when it is combined with Teriflunomide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Teriflunomide is combined with E-6201.Investigational
Edetic AcidTeriflunomide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTeriflunomide may increase the anticoagulant activities of Edoxaban.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Teriflunomide.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Teriflunomide.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Teriflunomide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Teriflunomide.Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Teriflunomide.Approved
EnoxacinTeriflunomide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTeriflunomide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Teriflunomide.Experimental
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Teriflunomide.Approved
EpanololTeriflunomide may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Epirizole.Approved
EpirubicinTeriflunomide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTeriflunomide may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Teriflunomide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Teriflunomide.Approved
EquileninThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Equilin.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Teriflunomide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Teriflunomide.Approved, Vet Approved
EsmololTeriflunomide may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Teriflunomide.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Teriflunomide.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Teriflunomide.Approved
Etacrynic acidTeriflunomide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Teriflunomide.Approved
EthenzamideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTeriflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Teriflunomide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Teriflunomide.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Teriflunomide.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Teriflunomide.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Teriflunomide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Teriflunomide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Teriflunomide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Feprazone.Experimental
Ferulic acidTeriflunomide may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Teriflunomide.Approved, Investigational
FingolimodTeriflunomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinTeriflunomide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Teriflunomide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fludrocortisone.Approved
FluindioneTeriflunomide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTeriflunomide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Teriflunomide.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluorometholone.Approved
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Teriflunomide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Teriflunomide.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Teriflunomide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Teriflunomide.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.Approved, Investigational
Folic AcidThe serum concentration of Folic Acid can be increased when it is combined with Teriflunomide.Approved, Nutraceutical, Vet Approved
FondaparinuxTeriflunomide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTeriflunomide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Teriflunomide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Teriflunomide.Approved
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Teriflunomide.Approved
FramycetinTeriflunomide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FrovatriptanThe serum concentration of Frovatriptan can be decreased when it is combined with Teriflunomide.Approved, Investigational
FurosemideTeriflunomide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Teriflunomide.Investigational
GabexateTeriflunomide may increase the anticoagulant activities of Gabexate.Investigational
Gadoxetic acidThe serum concentration of Gadoxetic acid can be increased when it is combined with Teriflunomide.Approved
GarenoxacinTeriflunomide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTeriflunomide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Teriflunomide.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Teriflunomide.Approved, Withdrawn
GemifloxacinTeriflunomide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTeriflunomide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinThe serum concentration of Genistein can be decreased when it is combined with Teriflunomide.Investigational
GentamicinTeriflunomide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATeriflunomide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Teriflunomide.Investigational
GimatecanThe serum concentration of Gimatecan can be increased when it is combined with Teriflunomide.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Teriflunomide.Approved
Glutaric AcidThe serum concentration of Glutaric Acid can be increased when it is combined with Teriflunomide.Experimental
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Teriflunomide.Approved
GPX-150Teriflunomide may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Teriflunomide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Teriflunomide.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Guacetisal.Experimental
GuanabenzThe serum concentration of Guanabenz can be decreased when it is combined with Teriflunomide.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Teriflunomide.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Teriflunomide is combined with HE3286.Investigational
HeparinTeriflunomide may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Teriflunomide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Teriflunomide.Approved, Withdrawn
HesperetinThe serum concentration of Hesperetin can be decreased when it is combined with Teriflunomide.Approved
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Teriflunomide.Approved
HigenamineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Higenamine.Investigational
HydralazineTeriflunomide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Teriflunomide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Teriflunomide.Approved, Investigational
Hygromycin BTeriflunomide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Teriflunomide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Teriflunomide.Approved
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Teriflunomide.Approved, Investigational
IdarubicinTeriflunomide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Teriflunomide.Approved
IdraparinuxTeriflunomide may increase the anticoagulant activities of Idraparinux.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Teriflunomide.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Teriflunomide.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Teriflunomide.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Teriflunomide.Approved, Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Teriflunomide.Approved
IndenololTeriflunomide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Indoprofen.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Teriflunomide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Teriflunomide.Investigational
INNO-206Teriflunomide may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Teriflunomide.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Teriflunomide.Approved, Investigational
IsepamicinTeriflunomide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Istaroxime.Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Teriflunomide.Approved, Vet Approved
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Teriflunomide.Approved
KanamycinTeriflunomide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Teriflunomide.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Teriflunomide.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Teriflunomide.Approved
LabetalolTeriflunomide may decrease the antihypertensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Teriflunomide.Approved, Investigational
LandiololTeriflunomide may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Teriflunomide.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Teriflunomide.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Teriflunomide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Teriflunomide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Teriflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Teriflunomide.Approved
LepirudinTeriflunomide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTeriflunomide may increase the anticoagulant activities of Letaxaban.Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Teriflunomide.Approved
LevobunololTeriflunomide may decrease the antihypertensive activities of Levobunolol.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Teriflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide.Approved, Investigational
LevomenolThe serum concentration of Levomenol can be increased when it is combined with Teriflunomide.Approved, Experimental
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.Approved
LevosalbutamolThe serum concentration of Levosalbutamol can be increased when it is combined with Teriflunomide.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Teriflunomide.Investigational
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Teriflunomide.Approved, Investigational
LiothyronineThe serum concentration of Liothyronine can be increased when it is combined with Teriflunomide.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be increased when it is combined with Teriflunomide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Teriflunomide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Teriflunomide.Approved
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Teriflunomide.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lonazolac.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Teriflunomide.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Teriflunomide.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Teriflunomide.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Teriflunomide.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Teriflunomide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Teriflunomide.Approved, Investigational
LumiracoxibThe serum concentration of Lumiracoxib can be decreased when it is combined with Teriflunomide.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Teriflunomide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Teriflunomide.Approved
MalathionThe serum concentration of Malathion can be decreased when it is combined with Teriflunomide.Approved, Investigational
MaprotilineThe serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Teriflunomide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Teriflunomide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Medrysone.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Teriflunomide.Approved
MelagatranTeriflunomide may increase the anticoagulant activities of Melagatran.Experimental
MelatoninThe serum concentration of Melatonin can be decreased when it is combined with Teriflunomide.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Melengestrol.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Teriflunomide.Approved, Vet Approved
MenadioneThe serum concentration of Menadione can be decreased when it is combined with Teriflunomide.Approved, Nutraceutical
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Teriflunomide.Investigational, Withdrawn
MepindololTeriflunomide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTeriflunomide may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Teriflunomide.Investigational, Withdrawn
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Teriflunomide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Teriflunomide.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTeriflunomide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.Approved
MetoprololTeriflunomide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTeriflunomide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Teriflunomide.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Teriflunomide.Approved, Investigational
MicronomicinTeriflunomide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Teriflunomide.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Teriflunomide.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Teriflunomide.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Teriflunomide.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Teriflunomide.Approved, Investigational
muraglitazarThe serum concentration of muraglitazar can be decreased when it is combined with Teriflunomide.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Teriflunomide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.Approved
NabumetoneThe serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.Approved
NadololTeriflunomide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTeriflunomide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTeriflunomide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Teriflunomide.Approved
Nalidixic AcidTeriflunomide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Teriflunomide.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Teriflunomide is combined with NCX 1022.Investigational
NeamineTeriflunomide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTeriflunomide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTeriflunomide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTeriflunomide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Teriflunomide.Approved
NetilmicinTeriflunomide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Nicardipine can be decreased when combined with Teriflunomide.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Teriflunomide.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Teriflunomide.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Teriflunomide.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Teriflunomide.Approved, Investigational, Withdrawn
Nitric OxideThe serum concentration of Nitric Oxide can be decreased when it is combined with Teriflunomide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Nitroaspirin.Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Teriflunomide.Approved, Vet Approved
NorfloxacinTeriflunomide may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Teriflunomide.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Teriflunomide.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Oleoyl-estrone.Investigational
OlmesartanThe serum concentration of Olmesartan can be increased when it is combined with Teriflunomide.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Teriflunomide.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.Approved
OlsalazineTeriflunomide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Teriflunomide.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Teriflunomide.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Teriflunomide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Teriflunomide.Approved
OtamixabanTeriflunomide may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Teriflunomide.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be decreased when it is combined with Teriflunomide.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Teriflunomide.Approved
Oxolinic acidTeriflunomide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTeriflunomide may decrease the antihypertensive activities of Oxprenolol.Approved
OxtriphyllineThe serum concentration of Oxtriphylline can be decreased when it is combined with Teriflunomide.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide.Approved, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Teriflunomide.Approved, Vet Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Teriflunomide.Approved, Investigational
PamidronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Teriflunomide.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Teriflunomide.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Teriflunomide.Approved
ParomomycinTeriflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.Approved
PazufloxacinTeriflunomide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTeriflunomide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTeriflunomide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PenicillamineThe serum concentration of Penicillamine can be increased when it is combined with Teriflunomide.Approved
Pentaerythritol TetranitrateTeriflunomide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide.Approved
Pentosan PolysulfateTeriflunomide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be decreased when it is combined with Teriflunomide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Teriflunomide.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Teriflunomide.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Teriflunomide.Withdrawn
PhenindioneTeriflunomide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTeriflunomide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Teriflunomide.Approved, Vet Approved
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Teriflunomide.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Teriflunomide.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Teriflunomide.Approved
PindololTeriflunomide may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Teriflunomide.Approved, Investigational
Pipemidic acidTeriflunomide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Teriflunomide.Approved, Investigational
PirarubicinTeriflunomide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTeriflunomide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Teriflunomide.Approved, Investigational
Piromidic acidTeriflunomide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Teriflunomide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Teriflunomide.Approved
Platelet Activating FactorTeriflunomide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTeriflunomide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTeriflunomide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Teriflunomide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Teriflunomide.Approved
PractololTeriflunomide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Teriflunomide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prasterone sulfate.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.Approved
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Teriflunomide.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pregnenolone.Experimental, Investigational
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Teriflunomide.Approved
ProbenecidThe serum concentration of Teriflunomide can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Proglumetacin.Experimental
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Teriflunomide.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Teriflunomide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Teriflunomide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Teriflunomide.Vet Approved
Protein CTeriflunomide may increase the anticoagulant activities of Protein C.Approved
Protein S humanTeriflunomide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTeriflunomide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTeriflunomide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Teriflunomide.Investigational
PuromycinTeriflunomide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Teriflunomide.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Teriflunomide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Teriflunomide.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Teriflunomide.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Teriflunomide.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Teriflunomide.Approved
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Teriflunomide.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Teriflunomide.Approved
RasagilineThe serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Teriflunomide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Teriflunomide.Approved
ResveratrolThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.Approved, Experimental, Investigational
ReviparinTeriflunomide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTeriflunomide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Teriflunomide.Approved
RifampicinThe metabolism of Rifampicin can be decreased when combined with Teriflunomide.Approved
RiluzoleThe serum concentration of Riluzole can be decreased when it is combined with Teriflunomide.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Teriflunomide.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Teriflunomide.Approved
RisedronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Risedronate.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Teriflunomide.Approved, Investigational
RivaroxabanTeriflunomide may increase the anticoagulant activities of Rivaroxaban.Approved
RizatriptanThe serum concentration of Rizatriptan can be decreased when it is combined with Teriflunomide.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Teriflunomide.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Teriflunomide.Approved
RolapitantThe serum concentration of Teriflunomide can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Teriflunomide.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Teriflunomide.Approved, Investigational
RosoxacinTeriflunomide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Teriflunomide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Teriflunomide.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Teriflunomide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Teriflunomide.Approved
RucaparibThe serum concentration of Rucaparib can be decreased when it is combined with Teriflunomide.Approved, Investigational
RufloxacinTeriflunomide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTeriflunomide may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Teriflunomide.Approved
SafinamideThe serum concentration of Safinamide can be increased when it is combined with Teriflunomide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Teriflunomide.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Teriflunomide.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Teriflunomide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Teriflunomide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Teriflunomide.Investigational
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Teriflunomide.Approved
SemapimodThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Semapimod.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Teriflunomide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Serrapeptase.Investigational
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Teriflunomide.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Teriflunomide.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Teriflunomide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teriflunomide.Approved
SisomicinTeriflunomide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTeriflunomide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Teriflunomide.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Teriflunomide.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Teriflunomide.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Teriflunomide.Approved, Investigational
SotalolTeriflunomide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTeriflunomide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTeriflunomide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTeriflunomide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Teriflunomide.Approved
SpironolactoneTeriflunomide may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Teriflunomide.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Teriflunomide.Investigational
StavudineThe serum concentration of Stavudine can be increased when it is combined with Teriflunomide.Approved, Investigational
StiripentolThe serum concentration of Stiripentol can be decreased when it is combined with Teriflunomide.Approved
StreptomycinTeriflunomide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTeriflunomide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Teriflunomide.Approved, Vet Approved
SulfasalazineThe serum concentration of Sulfasalazine can be increased when it is combined with Teriflunomide.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Teriflunomide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Teriflunomide.Approved
SulodexideTeriflunomide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Teriflunomide.Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Teriflunomide.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Teriflunomide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be decreased when it is combined with Teriflunomide.Investigational, Withdrawn
TacrolimusTeriflunomide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Teriflunomide.Approved
TalinololTeriflunomide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Teriflunomide.Approved
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Teriflunomide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Teriflunomide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Teriflunomide.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Teriflunomide.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Teriflunomide.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Teriflunomide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m mebrofeninThe serum concentration of Technetium Tc-99m mebrofenin can be increased when it is combined with Teriflunomide.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Technetium Tc-99m medronate.Approved
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Teriflunomide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Teriflunomide.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Teriflunomide.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Teriflunomide.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Teriflunomide.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Teriflunomide.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Teriflunomide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tepoxalin.Vet Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Teriflunomide.Approved, Investigational, Vet Approved
TertatololTeriflunomide may decrease the antihypertensive activities of Tertatolol.Experimental
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Teriflunomide.Approved, Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Teriflunomide.Investigational
ThalidomideThe serum concentration of Thalidomide can be decreased when it is combined with Teriflunomide.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be decreased when it is combined with Teriflunomide.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Teriflunomide.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Teriflunomide.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Teriflunomide.Approved, Withdrawn
ThiothixeneThe serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Teriflunomide.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTeriflunomide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tixocortol.Approved
TizanidineThe serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.Approved
TobramycinTeriflunomide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibTeriflunomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Teriflunomide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Teriflunomide.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Teriflunomide.Approved, Investigational
TorasemideTeriflunomide may decrease the diuretic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Teriflunomide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Teriflunomide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Teriflunomide.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Teriflunomide.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Teriflunomide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Teriflunomide.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Teriflunomide.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.Approved
TribenosideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Teriflunomide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Teriflunomide.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Teriflunomide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triptolide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Teriflunomide.Investigational, Withdrawn
TrovafloxacinTeriflunomide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTeriflunomide may increase the anticoagulant activities of Troxerutin.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Teriflunomide.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Teriflunomide.Approved
VadimezanThe serum concentration of Vadimezan can be decreased when it is combined with Teriflunomide.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Teriflunomide.Investigational, Withdrawn
ValrubicinTeriflunomide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Teriflunomide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Teriflunomide.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Teriflunomide.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Teriflunomide.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Teriflunomide.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Teriflunomide.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Teriflunomide.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Teriflunomide.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Teriflunomide.Approved
XimelagatranTeriflunomide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Teriflunomide.Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Teriflunomide.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Teriflunomide.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Teriflunomide.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Teriflunomide.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Teriflunomide.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Teriflunomide.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Zoledronic acid.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be decreased when it is combined with Teriflunomide.Approved, Investigational
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Teriflunomide.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Teriflunomide.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Teriflunomide.Approved
Zoptarelin doxorubicinTeriflunomide may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTeriflunomide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Teriflunomide.Approved
Food Interactions
  • Food does not affect teriflunomide pharmacokinetics, so take with or without food.

References

Synthesis Reference

Keshav Deo, Samir Patel, Snehal Dhol, Sunil Sanghani, Vishal Ray, " PROCESS FOR PREPARING TERIFLUNOMIDE." U.S. Patent US20110092727, issued April 21, 2011.

US20110092727
General References
  1. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894-900. [PubMed:16567708]
  2. Tallantyre E, Evangelou N, Constantinescu CS: Spotlight on teriflunomide. Int MS J. 2008 Jun;15(2):62-8. [PubMed:18782502]
External Links
KEGG Drug
D10172
PubChem Compound
54684141
PubChem Substance
347827807
ChemSpider
16737143
BindingDB
50018011
ChEBI
68540
ChEMBL
CHEMBL973
HET
A26
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Teriflunomide
ATC Codes
L04AA31 — Teriflunomide
AHFS Codes
  • 92:20.00 — Immunomodulatory Agents
PDB Entries
1d3h / 1tv5
FDA label
Download (527 KB)
MSDS
Download (124 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedNot AvailableHealthy Volunteers / Teriflunomide Elimination1
2CompletedNot AvailableDisseminated Sclerosis1
2CompletedTreatmentDisseminated Sclerosis5
3Active Not RecruitingTreatmentDisseminated Sclerosis / Relapsing Multiple Sclerosis (RMS)1
3CompletedTreatmentDisseminated Sclerosis5
3Not Yet RecruitingTreatmentDisseminated Sclerosis2
3RecruitingTreatmentDisseminated Sclerosis1
3RecruitingTreatmentRelapsing Multiple Scelrosis1
3RecruitingTreatmentRelapsing Multiple Sclerosis (RMS)3
3TerminatedTreatmentRelapsing Multiple Sclerosis (RMS)1
4Active Not RecruitingTreatmentDisseminated Sclerosis1
4CompletedTreatmentDisseminated Sclerosis1
Not AvailableEnrolling by InvitationNot AvailableRelapsing Remitting Multiple Sclerosis (RRMS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral14 mg
Tablet, film coatedOral14 mg
Tablet, film coatedOral14 mg/1
Tablet, film coatedOral7 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6794410No2002-04-152022-04-15Us
US9186346No2014-02-042034-02-04Us
US8802735No2010-09-142030-09-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble in DMSO (practically insoluble in water).From FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.0124 mg/mLALOGPS
logP2.3ALOGPS
logP2.14ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)5.48ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area73.12 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.39 m3·mol-1ChemAxon
Polarizability23.15 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Anilides / N-arylamides / Vinylogous acids / Secondary carboxylic acid amides / Nitriles / Enols / Organopnictogen compounds / Organofluorides / Organic oxides / Hydrocarbon derivatives
show 2 more
Substituents
Trifluoromethylbenzene / Anilide / N-arylamide / Vinylogous acid / Carboxamide group / Secondary carboxylic acid amide / Carboxylic acid derivative / Enol / Carbonitrile / Nitrile
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
nitrile, enamide, aromatic amide, enol, (trifluoromethyl)benzenes (CHEBI:68540)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquinone binding
Specific Function
Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
Gene Name
DHODH
Uniprot ID
Q02127
Uniprot Name
Dihydroorotate dehydrogenase (quinone), mitochondrial
Molecular Weight
42866.93 Da
References
  1. Palmer AM: Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010 Nov;11(11):1313-23. [PubMed:21157651]
  2. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [PubMed:8573583]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P: Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7. doi: 10.1136/ard.2007.086264. Epub 2008 Apr 8. [PubMed:18397960]

Drug created on May 19, 2013 20:55 / Updated on November 22, 2017 12:37